Rifapentine is an anti-mycobacterial drug that was approved in the United States as a treatment for tuberculosis in 1998. Rifapentine should be taken in combination with other anti-tuberculosis drugs.

It is manufactured by Hoechst Marion Rousel.

Rifapentine is taken intensively for the first two months of treatment, and then is taken once a week for four months.

The effectiveness of rifapentine as a treatment for tuberculosis has not been proven in people with HIV. There is evidence that rifapentine may be an inferior treatment option for people with HIV due to an increased chance of resistance to the rifamycins, including rifapentine and the related drug rifampicin (Rifadin / Rimactane). A randomised trial comparing rifapentine with rifampicin, both in combination with isoniazid in 71 HIV-positive people with tuberculosis found that four people on rifapentine developed drug resistance compared with none of the rifampicin group. The authors recommended the once weekly rifapentine and isoniazid should not be used among people with HIV.1

People who are on protease inhibitors should not take rifapentine due to drug interactions.


  1. Vernon A et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 353: 1843, 1999

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.